SG11202104585YA - Pyrazoles as modulators of hemoglobin - Google Patents

Pyrazoles as modulators of hemoglobin

Info

Publication number
SG11202104585YA
SG11202104585YA SG11202104585YA SG11202104585YA SG11202104585YA SG 11202104585Y A SG11202104585Y A SG 11202104585YA SG 11202104585Y A SG11202104585Y A SG 11202104585YA SG 11202104585Y A SG11202104585Y A SG 11202104585YA SG 11202104585Y A SG11202104585Y A SG 11202104585YA
Authority
SG
Singapore
Prior art keywords
pyrazoles
hemoglobin
modulators
Prior art date
Application number
SG11202104585YA
Other languages
English (en)
Inventor
Ariamala Gopalsamy
Arjun Venkat Narayanan
Agustin Casimiro-Garcia
Chulho Choi
David Hepworth
David Walter Piotrowski
Hatice Gizem Yayla
Jayasankar Jasti
Lee Richard Roberts
Lyn Howard Jones
Mihir Dineshkumar Parikh
Ming Zhu Chen
Olugbeminiyi Omezia Fadeyi
Robinson, Jr
Robert Lee Dow
Shawn Cabral
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11202104585YA publication Critical patent/SG11202104585YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202104585YA 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin SG11202104585YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772815P 2018-11-29 2018-11-29
US201962915784P 2019-10-16 2019-10-16
PCT/IB2019/060171 WO2020109994A1 (en) 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin

Publications (1)

Publication Number Publication Date
SG11202104585YA true SG11202104585YA (en) 2021-06-29

Family

ID=68807213

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104585YA SG11202104585YA (en) 2018-11-29 2019-11-26 Pyrazoles as modulators of hemoglobin

Country Status (22)

Country Link
US (3) US11014908B2 (ko)
EP (1) EP3886984A1 (ko)
JP (1) JP2022510628A (ko)
KR (1) KR20210097161A (ko)
CN (1) CN113329789A (ko)
AU (1) AU2019387290A1 (ko)
BR (1) BR112021009057A2 (ko)
CA (1) CA3121139A1 (ko)
CO (1) CO2021006924A2 (ko)
CR (1) CR20210284A (ko)
CU (1) CU20210044A7 (ko)
DO (1) DOP2021000103A (ko)
EC (1) ECSP21037191A (ko)
IL (1) IL283408A (ko)
MA (1) MA54283A (ko)
MX (1) MX2021006095A (ko)
PE (1) PE20211592A1 (ko)
PH (1) PH12021551035A1 (ko)
SG (1) SG11202104585YA (ko)
TW (2) TW202140452A (ko)
UY (1) UY38488A (ko)
WO (1) WO2020109994A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210284A (es) * 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina
IL294921A (en) 2020-01-24 2022-09-01 Pfizer Antibodies against E-selectin, preparations and methods of use
CN112079774A (zh) * 2020-10-17 2020-12-15 甘肃天后光学科技有限公司 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
WO2011015524A2 (en) 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Alk阻害剤としての複素環式誘導体
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
ES2963218T3 (es) * 2011-12-28 2024-03-25 Global Blood Therapeutics Inc Productos intermedios para obtener compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular
US20140271591A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US20160083343A1 (en) 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105209469A (zh) 2013-03-15 2015-12-30 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) * 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9248199B2 (en) * 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
US9920072B2 (en) 2014-11-03 2018-03-20 Hoffmann-La Roche Inc. BACE1 inhibitors
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
CA3158951A1 (en) 2016-08-15 2018-02-22 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
CR20210284A (es) * 2018-11-29 2021-07-09 Pfizer Pirazoles como modulares de hemoglobina

Also Published As

Publication number Publication date
EP3886984A1 (en) 2021-10-06
TW202033513A (zh) 2020-09-16
CU20210044A7 (es) 2022-01-13
KR20210097161A (ko) 2021-08-06
MX2021006095A (es) 2021-07-06
CO2021006924A2 (es) 2021-06-10
MA54283A (fr) 2022-03-09
TWI736037B (zh) 2021-08-11
PH12021551035A1 (en) 2021-12-06
JP2022510628A (ja) 2022-01-27
TW202140452A (zh) 2021-11-01
PE20211592A1 (es) 2021-08-18
DOP2021000103A (es) 2021-07-30
ECSP21037191A (es) 2021-06-30
AU2019387290A1 (en) 2021-05-27
US11014908B2 (en) 2021-05-25
IL283408A (en) 2021-07-29
CA3121139A1 (en) 2020-06-04
US20200172512A1 (en) 2020-06-04
UY38488A (es) 2020-06-30
CR20210284A (es) 2021-07-09
US11702405B2 (en) 2023-07-18
US20230382892A1 (en) 2023-11-30
CN113329789A (zh) 2021-08-31
BR112021009057A2 (pt) 2021-08-10
WO2020109994A1 (en) 2020-06-04
US20220348555A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
IL271948A (en) Carboxamides as modulators of sodium channels
IL283582A (en) ror - gamma modulators
HK1255699A1 (zh) Kras表達的調節劑
HK1256599A1 (zh) ROR-γ的調節劑
HK1250999A1 (zh) Ror1-ror2結合的調節劑
IL283128A (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
IL281492A (en) Modulators of PNPLA3 expression
IL283408A (en) Pyrazoles as modulators of hemoglobin
IL283967A (en) Modulators of hsd17b13 expression
IL267994A (en) Bis-heteroaryl compounds as modulators of protein aggregation
EP3364974A4 (en) MODULATORS OF TELOMIC DISEASE
IL304618A (en) Modulators of pcsk9 expression
ZA202007537B (en) Modulators of apol1 expression
PL3449931T3 (pl) Zastosowanie cerebrolizyny
IL274231A (en) Modulators of ENAC expression
IL276007A (en) Modulators for dnm2 expression
IL271359A (en) Modulators of alpha-synuclein
IL285333A (en) Modulators of malat1 expression
SG11202105136WA (en) Application of chidamide
SG11202010971XA (en) Small molecule modulators of mhc-i
IL271332A (en) Tetrahydropyridopyrazine modulators of GPR6